Allotex Announces New Investor and Expansion of Production Facilities USA - English USA - English

BOSTON and MILAN, Nov. 30, 2023 ~ Allotex Inc. and SpA, a leading biologics and device company specializing in vision correction therapies, has announced that Junson Capital has joined its investor syndicate. This additional capital will help support the expansion of the Company's production facility in preparation for market introduction and US clinical trials.

Dr. David Muller, Founder and CEO of Allotex, commented on the company's progress, saying, "This financing will allow Allotex to introduce our groundbreaking technology in Europe and Japan in early 2024 while actively working with the FDA to initiate clinical trials in the United States as soon as possible. The additional capital will help support the necessary expansion of our production facilities to increase capacity and ensure a steady supply of products."

Allotex's innovative approach uses laser-shaped human corneal allografts to reshape the cornea for the treatment of presbyopia, restoring lost reading vision which is caused by the natural aging process. With hundreds of millions of individuals worldwide seeking a safe, effective, and long-lasting alternative to spectacles and contact lenses for reading, Allotex is poised to make a major impact in the vison care marketplace.

More on Boston Chron
John White, Allotex Board member representing KCK MedTech commented on their published safety and efficacy results along with their 4-year follow-up saying it would boost market acceptance for both patients and refractive surgeons. He added that surgeons have had confidence in using human corneal allografts for over 70 years and are excited about the potential for their technology to restore reading vision to millions of people who have age related presbyopia.

Junson Capital has joined existing investors including KCK MedTech, Panakes, Supernova Invest, and Exor Ventures to complete the Series B financing. Wei Shen from Junson Capital expressed enthusiasm for joining the investor syndicate stating they were excited to partner with Allotex and contribute to advancing their groundbreaking therapies with potential to make a significant impact on global vision-correction market. Junson Capital is a global investment manager with long dedication to disruptive technology and healthcare leaders across venture capital, private equity, public markets, real estate and alternatives. Allotex was advised by Cukierman & Co. Life Sciences for this transaction.
Filed Under: Business

Show All News | Report Violation


Latest on Boston Chron